Role of P14 and MGMT Gene Methylation in Hepatocellular Carcinomas: a Meta-analysis

  • Li, Cheng-Cheng (Department of Public Health, Qingdao University Medical College) ;
  • Yu, Zhuang (Department of Oncology, the Affiliated Hospital of Medical College Qingdao University) ;
  • Cui, Lian-Hua (Department of Public Health, Qingdao University Medical College) ;
  • Piao, Jin-Mei (Department of Public Health, Qingdao University Medical College) ;
  • Liu, Meng (Department of Public Health, Qingdao University Medical College)
  • Published : 2014.08.30


Background: This meta-analysis was performed to investigate the relationship between methylation of the P14 and O6-methylguanine-DNA methyltransferase (MGMT) genes and the risk of hepatocellular carcinoma (HCC). Materials and Methods: We searched PubMed, EMBASE, the Chinese Biomedical Database (CBM), and the China National Knowledge Infrastructure (CNKI) databases to identify relevant studies that analysed HCC tissues for P14 and MGMT gene methylation status; we then performed a meta-analysis. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated to evaluate the association between gene methylation and the risk of HCC. Results: Ten studies that assessed P14 gene methylation in 630 HCC tumour tissues and nine studies analysing MGMT methylation in 497 HCC tumour tissues met our inclusion criteria. Our meta-analysis revealed that the rate of P14 methylation was significantly higher in HCCs than in adjacent tissues (OR 3.69, 95%CI 1.63-8.35, p=0.002), but there was no significant difference in MGMT methylation between HCC and adjacent tissues (OR 1.76, 95%CI 0.55-5.64, p=0.34). A subgroup analysis according to ethnicity revealed that P14 methylation was closely related to the risk of HCC in Chinese and Western individuals (Chinese, OR 7.74, 95%CI 1.36-44.04, p=0.021; Western, OR 3.60, 95%CI 1.49-8.69, p=0.004). Furthermore, MGMT methylation was not correlated with the risk of HCC in Chinese individuals (OR 2.42, 95%CI 0.76-7.73, p=0.134). The combined rate of P14 methylation was 35% (95%CI 24-48%) in HCC tumour tissues and 11% (95%CI 4-27%) in adjacent tissues, whereas the combined rate of MGMT methylation was 15% (95%CI 6-32%) in HCC and 10% (95%CI 4-22%) in adjacent tissues. Conclusions: These results suggest that the risk of HCC is related to P14 methylation, but not MGMT methylation. Therefore, P14 gene methylation may be a potential biomarker for the diagnosis of HCC.


Methylation;P14;MGMT;hepatocellular carcinoma;meta-analysis


  1. Ael-R Z, Nassar AA, El-Din EMN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6.
  2. Anzola M, Cuevas N, Lopez-Martinez M, et al (2004). P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 16, 19-26.
  3. Citron M, Decker R, Chen S, et al (1991). O6-methylguanine- DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res, 51, 4131-4.
  4. Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  5. Esteller M (2006). Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer, 94, 179-83.
  6. Esteller M, Hamilton SR, Burger PC, et al (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res, 59, 793-7.
  7. Fleiss JL (1993). The statistical basis of meta-analysis. Stat Methods Med Res, 2, 121-45.
  8. Formeister EJ, Tsuchiya M, Fujii H, et al (2010). Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res, 692, 26-33.
  9. Gu C, Lu J, Cui T, et al (2013). Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One, 8, e7263.
  10. He J, Qiao JB, Zhu H (2011). p14ARF promoter region methylation as a marker for gliomas diagnosis. Med Oncol, 28, 1218-24.
  11. Herath NI, Purdie DM, Kew MC, et al (2009). Varying etiologies lead to different molecular changes in Australian and South African hepatocellular carcinomas. Int J Oncol, 35, 1081-9.
  12. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  13. Iakova P, Timchenko L, Timchenko NA (2011). Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol, 21, 28-34.
  14. Ishikawa T, Zhang SS, Qin X, et al (2004). DNA repair and cancer: lessons from mutant mouse models. Cancer Sci, 95, 112-7.
  15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  16. Kim YT, Lee SH, Sung SW, Kim JH (2005). Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection. Ann Thorac Surg, 79, 1180-8.
  17. Kupcinskaite-Noreikiene R, Skieceviciene J, Jonaitis L, et al (2013). CpG island methylation of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent noncancerous stomach tissues. Medicina, 49, 361-6.
  18. Laing ME, Cummins R, O'Grady A, et al (2010). Aberrant DNA methylation associated with MTHFR C677T genetic polymorphism in cutaneous squamous cell carcinoma in renal transplant patients. Br J Dermatol, 163, 345-52.
  19. Li B, Liu W, Wang L, et al (2010). CpG island methylator phenotype associated with tumor recurrence in tumor-nodemetastasis stage I hepatocellular carcinoma. Ann Surg Oncol, 17, 1917-26.
  20. Li H, Gao B, Yu Z, Liu J, Zhang J (2013). Significance of detection of mutigene methylation in liver cancer tissues for early diagnosis of liver cancer. J Clin Hepatol, 29, 624-6.
  21. Liu W, Wang L, Wang J, et al (2006). Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma. Ai Zheng, 25, 696-700.
  22. Lou C, Yang B, Gao Y, et al (2008). Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi, 30, 831-6.
  23. Luo M, Tang H, Zhou Q, et al (2013). Realizing the meta-analysis of single rate in R software. J Evidence-based Medicine, 13, 181-8.
  24. Moribe T, Iizuka N, Miura T, et al (2009). Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer, 125, 388-97.
  25. Nomoto S, Kinoshita T, Kato K, et al (2007). Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer, 97, 1260-5.
  26. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713-23.
  27. Qian B, Zhu L, Geng X, et al (2005). Methylation of MGMT, DAPK, THBS1 and RIZ1 genes in hepatocellular carcinoma. Chin J Gen Surg, 20, 291-4.
  28. Ruan X, Wang S, Chen X, Ren P (2007). 5' CpG methylation of P14ARF gene in hepatocellular carcinoma. Chin J Gen Surg, 22, 848-50.
  29. Saelee P, Chuensumran U, Wongkham S, et al (2012). Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 13, 3489-93.
  30. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5.
  31. Su PF, Lee TC, Lin PJ, et al (2007). Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer, 121, 1257-64.
  32. Tannapfel A, Busse C, Weinans L, et al (2001). INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene, 20, 7104-9.
  33. Tian K, Lin L, Jia T, Guo X, Zhang L (2006). Promoter methylation status and protein expression of p14ARF gene in squamous cell carcinoma and adenocarcinoma of the lung. Zhongguo Fei Ai Za Zhi, 9, 40-44.
  34. Yang B, Guo M, Herman JG, Clark DP (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 163, 1101-7.
  35. Yu J, Ni M, Xu J, et al (2002). Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer, 2, 29.
  36. Yu J, Zhang HY, Ma ZZ, et al (2003). Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res, 13, 319-33.
  37. Zhang C, Guo X, Zhang L, et al (2008). Methylation-related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma. J Surg Oncol, 98, 462-8.
  38. Zhang C, Li Z, Cheng Y, et al (2007). CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res, 13, 944-52.
  39. Zhang JC, Gao B, Yu ZT, et al (2014). Promoter hypermethylation of p14 (ARF) , RB, and INK4 gene family in hepatocellular carcinoma with hepatitis B virus infection. Tumour Biol, 35, 2795-802.
  40. Zhang Y, Xiong Y, Yarbrough WG (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-34.

Cited by

  1. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival vol.96, pp.38, 2017,